PharmaDeals Review: Latest Articles
All the latest analysis of deal-making activity in the pharmaceutical and biotechnology sector provided by the experts from the PharmaDeals Review.
- Published on: 2008-11-11 Zydus Cadila Enters Vaccines Market by Acquiring Etna Biotech Indian Pharmaceutical company, Zydus Cadila, has stepped into the vaccines market with the acquisition of vaccine developer, Etna Biotech, a subsidiary of Crucell NV of The Netherlands. The acquisition will bring cutting edge expertise in vaccine technology and products to Zydus Cadila, an area in which it was aspiring to gain a stronger foothold.
- Published on: 2008-11-06 Eli Lilly Steps Up Pharmacogenetics Effort Eli Lilly’s commitment to personalised medicine is demonstrated with its latest agreement with pharmacogenetics company, Cabernet Pharmaceuticals. Lilly sees the application of a pharmacogenetics approach to some of its drug development programmes as an important strategy in developing competitive drugs that could counteract imminent patent expiries of some of its major drugs.
- Published on: 2008-11-04 Genzyme and Osiris Sign Deal for First-in-Class Adult Stem Cell Products Osiris Therapeutics and Genzyme struck a marketing deal for two adult stem cell treatments, Prochymal and Chondrogen, both of which are in clinical trials. This important deal will strengthen Genzyme’s late stage pipeline in transplantation rejection and inflammatory disease.
- Published on: 2008-10-29 GSK Acquires Genelabs to Boost its HCV Pipeline GlaxoSmithKline (GSK) is to acquire Genelabs Technologies for US$57 M in a deal which will boost GSK’s hepatitis C virus (HCV) pipeline. With growing patient numbers and poor treatment options, there is a high unmet need for new HCV therapies - and therefore huge rewards to be made from developing a successful new treatment.
- Published on: 2008-10-29 Merck Serono Signs North American Deals Merck Serono signed two deals in the areas of HIV-related lipodystrophy with Theratechnologies and with Lpath for monoclonal antibodies to treat cancer. The German group, Merck KGaA, has been realigning its business since the purchase of Serono to focus on research-driven pharmaceuticals and biotech products.
- Published on: 2008-10-29 Recordati Enters Turkey with the Acquisition of Yeni Ilac Recordati has established a subsidiary in Turkey through its latest acquisition of the Turkish company, Yeni Ilac, for €48 M (US$60 M). Turkey’s growing economy has spurred this acquisition and Recordati will take full advantage of Yeni Ilac’s strong presence in the Turkish market to sell its own products.
- Published on: 2008-10-20 Pfizer and UCB Join Forces on Drug Discovery Efforts UCB and Pfizer are collaborating to establish a new technology company called Cyclofluidic set up under a public-private partnership initiative by the UK’s Technology Strategy Board. It is hoped that the automated flow chemistry and flow biology techniques, to be developed by the company, will speed up and cut costs of the drug development process.
- Published on: 2008-10-16 Progenics Outlicenses Japanese Rights to Relistor® Ono Pharmaceutical is to develop Relistor® (methylnaltrexone bromide) for the Japanese market, following a licensing deal with Progenics Pharmaceuticals. The recently launched product is the first medicine approved for the treatment of opioid-induced constipation in advanced illness patients, and has been co-developed with Wyeth.
- Published on: 2008-10-15 GSK Seeks Growth in Emerging Markets GlaxoSmithKline agreed to acquire Bristol-Myers Squibb’s portfolio of mature products in Egypt in a move that confirms a shift in GSK’s strategy to capitalise on its marketing strength to increase its presence in emerging economies, which includes the Middle East and North African regions.
- Published on: 2008-10-14 Alcon Expands Drug Portfolio with GSK and Origenis Deals Alcon has signed two deals to expand its future drug portfolio, that includes gaining a licence for troubled GlaxoSmithKline product, cilomilast. The leading eye care company also announced a rise in third quarter global sales this week but investors’ attention was apparently focused on Alcon cutting its revenue outlook, causing a dramatic drop in the company’s share price.
Review and Analysis, Navigation
Bookmarks
Bookmark PharmaDeals through one of these social networks.
